Clinical Trial

International Myeloma Foundation Launches Clinical Trial Matching Engine in Partnership with SparkCures

SparkCures’ best-in-class clinical trial matching and navigation service is now accessible via myeloma.org.STUDIO CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE)…

1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

1 year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company…

1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member CouncilATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) --…

1 year ago

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical…

1 year ago

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) --…

1 year ago

Celly Nutrition Launches unbuzzd(TM) Post-Alcohol Consumption Recovery Supplement in 18 Packs on Amazon

Vancouver, British Columbia--(Newsfile Corp. - October 10, 2024) - Celly Nutrition Corp. ("Celly Nu" or the "Company")") announces the release…

1 year ago

Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Financial HighlightsDirect MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, from CHF…

1 year ago

Cantargia’s Strong Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab Published in Clinical Cancer Research

LUND, SWEDEN / ACCESSWIRE / October 10, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the…

1 year ago

Laxxon Medical to Attend CPHI Milan 2024, Showcasing the cGMP Printing Technology at Adare Pharma Solution’s Facility in Pessano, Italy

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Laxxon Medical, a US-based pharma-technology company pioneering a new generation…

1 year ago